Xention Pharma Limited
http://www.xention.com/
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Latest From Xention Pharma Limited
PlaqueTec Appoints CEO
PlaqueTec, Ltd., a company focused on developing biomarker based therapies for coronary artery disease, has appointed Dr. Tim Brears CEO. Previously Brears was CEO of a company he founded in 2002, Xention Limited, which develops drugs for atrial fibrillation. Prior to this, Brears was CEO of a gene-regulation company, Gendaq Limited (acquired by Sangamo Biosciences).
Verona Adds Two Board Members
Verona Pharma plc, a drug development company focused on respiratory diseases, has appointed Ken Cunningham and Dr. Anders Ullman to its board of directors as non-executive directors – effective Sep. 10, 2015.
Life Science Start-Ups: Venture Funding, February 2014
Derived from Strategic Transactions, a fully searchable premium source for tracking life sciences deal activity, the Venture Funding column provides a comprehensive monthly review of emerging life science companies that have received venture funding, including companies within the In Vitro Diagnostics, Medical Devices, and Pharmaceuticals sectors. This month’s column covers deals announced December 2013 through January 2014.
U.K.’s Ario Pharma Raises $3M Series A For Cough Therapy
New spin-out Ario Pharma is targeting idiopathic cough and cough associated with COPD for Phase II studies of its TRPV1 ion channel antagonist, supported by $3 million in financing from VCs in the U.S. and Europe.
Company Information
- Industry
- Pharmaceuticals
- Other Names / Subsidiaries
-
- Xention Discovery Ltd.
- Xention Ltd.
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Email Company
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice